A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT ID: NCT06433752
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2024-07-22
2027-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT07225361
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
NCT06433765
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
NCT03277248
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
NCT06864936
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
NCT03277261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BRIUMVI® (Ublituximab-xiiy)
Participants will receive BRIUMVI® (Ublituximab-xiiy) intravenous (IV) infusion for the treatment of RMS.
No Intervention
No Intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
No Intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.
Exclusion Criteria
2. Any active infection (e.g., active Hepatitis B virus \[HBV\])
3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TG Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TG Therapeutics Investigational Trial Site
Birmingham, Alabama, United States
TG Therapeutics Investigational Trial Site
Mobile, Alabama, United States
TG Therapeutics Investigational Trial Site
Gilbert, Arizona, United States
TG Therapeutics Investigational Trial Site
Phoenix, Arizona, United States
TG Therapeutics Investigational Trial Site
Scottsdale, Arizona, United States
TG Therapeutics Investigational Trial Site
Newport Beach, California, United States
TG Therapeutics Investigational Trial Site
Orange, California, United States
TG Therapeutics Investigational Trial Site
West Hollywood, California, United States
TG Therapeutics Investigational Trial Site
Aurora, Colorado, United States
TG Therapeutics Investigational Trial Site
Basalt, Colorado, United States
TG Therapeutics Investigational Trial Site
Colorado Springs, Colorado, United States
TG Therapeutics Investigational Trial Site
Denver, Colorado, United States
TG Therapeutics Investigational Trial Site
Fort Collins, Colorado, United States
TG Therapeutics Investigational Trial Site
Grand Junction, Colorado, United States
TG Therapeutics Investigational Trial Site
Farmington, Connecticut, United States
TG Therapeutics Investigational Trial Site
Hartford, Connecticut, United States
TG Therapeutics Investigational Trial Site
Wilmington, Delaware, United States
TG Therapeutics Investigational Trial Site
Washington D.C., District of Columbia, United States
TG Therapeutics Investigational Trial Site
Altamonte Springs, Florida, United States
TG Therapeutics Investigational Trial Site
Boca Raton, Florida, United States
TG Therapeutics Investigational Trial Site
Clearwater, Florida, United States
TG Therapeutics Investigational Trial Site
Maitland, Florida, United States
TG Therapeutics Investigational Trial Site
Miami, Florida, United States
TG Therapeutics Investigational Trial Site
Naples, Florida, United States
TG Therapeutics Investigational Trial Site
Weston, Florida, United States
TG Therapeutics Investigational Trial Site
Atlanta, Georgia, United States
TG Therapeutics Investigational Trial Site
Atlanta, Georgia, United States
TG Therapeutics Investigational Trial Site
Coeur d'Alene, Idaho, United States
TG Therapeutics Investigational Trial Site
Chicago, Illinois, United States
TG Therapeutics Investigational Trial Site
Evanston, Illinois, United States
TG Therapeutics Investigational Trial Site
Urbana, Illinois, United States
TG Therapeutics Investigational Trial Site
Lexington, Kentucky, United States
TG Therapeutics Investigational Trial Site
Louisville, Kentucky, United States
TG Therapeutics Investigational Trial Site
Baltimore, Maryland, United States
TG Therapeutics Investigational Trial Site
Glen Burnie, Maryland, United States
TG Therapeutics Investigational Trial Site
Boston, Massachusetts, United States
TG Therapeutics Investigational Trial Site
Burlington, Massachusetts, United States
TG Therapeutics Investigational Trial Site
Norfolk, Massachusetts, United States
TG Therapeutics Investigational Trial Site
Ann Arbor, Michigan, United States
TG Therapeutics Investigational Trial Site
Farmington, Michigan, United States
TG Therapeutics Investigational Trial Site
Owosso, Michigan, United States
TG Therapeutics Investigational Trial Site
Omaha, Nebraska, United States
TG Therapeutics Investigational Trial Site
Las Vegas, Nevada, United States
TG Therapeutics Investigational Trial Site
Freehold, New Jersey, United States
TG Therapeutics Investigational Trial Site
Livingston, New Jersey, United States
TG Therapeutics Investigational Trial Site
Neptune City, New Jersey, United States
TG Therapeutics Investigational Trial Site
Teaneck, New Jersey, United States
TG Therapeutics Investigational Trial Site
Amherst, New York, United States
TG Therapeutics Investigational Trial Site
New York, New York, United States
TG Therapeutics Investigational Trial Site
Charlotte, North Carolina, United States
TG Therapeutics Investigational Trial Site
New Bern, North Carolina, United States
TG Therapeutics Investigational Trial Site
Raleigh, North Carolina, United States
TG Therapeutics Investigational Trial Site
Centerville, Ohio, United States
TG Therapeutics Investigational Trial Site
Centerville, Ohio, United States
TG Therapeutics Investigational Trial Site
Cincinnati, Ohio, United States
TG Therapeutics Investigational Trial Site
Cleveland, Ohio, United States
TG Therapeutics Investigational Trial Site
Columbus, Ohio, United States
TG Therapeutics Investigational Trial Site
Toledo, Ohio, United States
TG Therapeutics Investigational Trial Site
Portland, Oregon, United States
TG Therapeutics Investigational Trial Site
Bethlehem, Pennsylvania, United States
TG Therapeutics Investigational Trial Site
Knoxville, Tennessee, United States
TG Therapeutics Investigational Trial Site
Nashville, Tennessee, United States
TG Therapeutics Investigational Trial Site
Austin, Texas, United States
TG Therapeutics Investigational Trial Site
Austin, Texas, United States
TG Therapeutics Investigational Trial Site
Austin, Texas, United States
TG Therapeutics Investigational Trial Site
Dallas, Texas, United States
TG Therapeutics Investigational Trial Site
Edinburg, Texas, United States
TG Therapeutics Investigational Trial Site
San Antonio, Texas, United States
TG Therapeutics Investigational Trial Site
Charlottesville, Virginia, United States
TG Therapeutics Investigational Trial Site
Norfolk, Virginia, United States
TG Therapeutics Investigational Trial Site
Vienna, Virginia, United States
TG Therapeutics Investigational Trial Site
Kirkland, Washington, United States
TG Therapeutics Investigational Trial Site
Morgantown, West Virginia, United States
TG Therapeutics Investigational Trial Site
Greenfield, Wisconsin, United States
TG Therapeutics Investigational Trial Site
Milwaukee, Wisconsin, United States
TG Therapeutics Investigational Trial Site
Neenah, Wisconsin, United States
TG Therapeutics Investigational Trial Site
Waukesha, Wisconsin, United States
TG Therapeutics Investigational Trial Site
Guaynabo, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TG1101-RMS406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.